我dentification of neoplasms expressing programmed cell death 1-ligand 1
免疫组织化学(IHC)
28-8
GpPDL1288
我sPDL1288IHC
PDL1
special
For information on selection of programmed cell death 1-ligand 1 (PD-L1) testing, seehttps://news.mayocliniclabs.com/pd-l1-by-immunohistochemistry/
将套件中包含的绿色病理地址标签连接到运输容器的外部。
需要病理/诊断报告和简短的病史,包括肿瘤的主要部位。
样品类型:组织
supplies:病理packaging Kit (T554)
收集说明:Formalin-fixed, paraffin-embedded tissue block; or 3 unstained glass, "positively charged" slides with 4-microns formalin-fixed, paraffin-embedded tissue
一种dditional Information:一张幻灯片将用苏木精和曙红染色并返回。
如果不以电子方式订购,请完成,打印并发送以下样品中的1个:
我mmunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request(T763)
肿瘤学test Request
湿/冷冻组织 Cytology smears nonformalin fixed tissue nonparaffin embedded tissue 非充电幻灯片 probeOn slides |
拒绝 |
specimen Type | temperature | 时间 | 特殊容器 |
---|---|---|---|
special | 一种mbient (preferred) | ||
refrigerated |
我dentification of neoplasms expressing programmed cell death 1-ligand 1
程序性细胞死亡1-RIGAND 1(PD-L1),也称为B7同源物1(B7-H1)或CD274,是一种跨膜蛋白,参与通过与受体程序性死亡蛋白的相互作用来调节细胞介导的免疫反应1(PD-1)。PD-L1已被确定为多种肿瘤中的预后和疗法标记。在膀胱,肺,胃和胃食管连接,结肠,卵巢,乳房,肾脏和黑色素瘤的癌中已经观察到PD-L1的过表达。
the results of the test will be reported in form of scores. The scoring system is based on type and origin of tumor. If additional interpretation or analysis is needed, order PATHC / Pathology Consultation along with this test.
临床前研究表明,肿瘤细胞中的阳性程序性细胞死亡1-凸出1凸(PD-L1)免疫组织化学可能预测免疫检查点抑制剂对治疗的肿瘤反应。该结果不应用作确定治疗的唯一因素,因为还研究了其他因素(例如,肿瘤突变负担和微卫星不稳定性)作为预测标记。
this test has been validated for non-decalcified paraffin-embedded tissue specimens fixed in 10% neutral-buffered formalin. This assay has not been validated on tissues subjected to the decalcification process or the use of alternative fixatives for bone and bone marrow specimens or cell blocks.
一种ge of a cut paraffin section can affect immunoreactivity. Stability thresholds vary widely among published literature and are antigen dependent. Best practice is for paraffin sections to be cut within 6 weeks.
1。Garcia A, Recondo G, Greco M et al: Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. Heliyon. 2020 Jun;6(6):e04117
2. Kintslera S,Cassataroa MA,Drosch M,Holenya P,Knuechel R,Braunschweig T:不同肿瘤中编程死亡配体(PD-L1)的表达。比较几个当前可用的抗体克隆和抗体分析的比较。Ann Diagn Pathol。2019年8月; 41:24-37
3。O'Malley DP,Yang Y,Boisot S等:参考实验室中多种人类肿瘤中PD-L1的免疫组织化学检测:基于62,896例的观察结果。mod pathol。2019年7月; 32(7):929-942
4。Koppel C,Schwellenbach H,Zielinski D等:使用不同染色平台上的抗体克隆28-8对PD-L1免疫组织化学染色方案的优化和验证。mod pathol。2018年11月; 31(11):1630-1644
5. Phillips T, Simmons P, Inzunza HD, et al: Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer. Appl Immunohistochem Mol Morphol. 2015 Sep;23(8):541-549
我mmunohistochemistry on sections of paraffin-embedded tissue using程序性细胞死亡1 rigand 1(PD-L1)克隆28-8。(未发表的Mayo方法)
从星期一到星期五
this test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.
88360
test Id | 测试订单名称 | 订单loinc值 |
---|---|---|
288PD | pd-L1 (28-8), SemiQuant IHC, Manual | 85148-5 |
result Id | test Result Name | result LOINC Value
一种pplies only to results expressed in units of measure originally reported by the performing laboratory. These values do not apply to results that are converted to other units of measure.
|
---|---|---|
609995 | 解释 | 83056-2 |
609996 | participated in the Interpretation | no LOINC Needed |
609997 | 报告以电子方式签名 | 19139-5 |
609998 | material Received | 81178-6 |
609999 | disclaimer | 62364-5 |
610000 | Case Number | 80398-1 |
Change Type | effective Date |
---|---|
new Test | 2021-10-05 |